Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dermatology

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Almirall launches call for proposals to better understand skin diseases

AlmirallShare has received around 600 proposals spanning 60 countries since 2017

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Almirall and EpimAb Biotherapeutics enter $210m bispecific antibody partnership

The agreement gives Almirall access to EpimAb’s FIT-Ig drug discovery platform

- PMLiVE

BMS shares positive three-year results for Sotyktu in plaque psoriasis

Up to 100 million people worldwide are affected by some form of the immune-mediated disease

EU flag

New EU study highlights psychological challenges of living with skin diseases

Almost half of European adults declared at least one dermatological disease

- PMLiVE

Disseminating Outcomes and Impact in Berlin

The Medscape Education Global team is looking forward to a busy time in Berlin at the EADV Congress 2023. During the congress, Medscape will be presenting five posters examining the...

Medscape Education Global

- PMLiVE

Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis

The drug has been recommended as a treatment option for adult and adolescent patients

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

LEO Pharma to acquire Timber Pharmaceuticals in deal worth up to $36m

The transaction gives LEO access to Timber’s lead investigational candidate, TMB-001

- PMLiVE

NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa

Approximately 670 people in England are expected to benefit from the skin-wound-healing treatment

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links